Compounded Wegovy and Zepbound may disappear under new FDA rulesThe FDA is restricting compound versions of popular weight-loss drugs due to increased supply from original manufacturers.
How little Denmark got homegrown giant Novo Nordisk to lower Ozempic pricesPharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-OldsNovo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)Ozempic's explosive sales growth reflects its successful transition from a diabetes treatment to a leading weight loss drug.
Weight-loss drug firm accused of prioritising profits after halting insulin pen productionNovo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030Ozempic, originally a diabetes treatment, has become a major weight loss drug, generating $14 billion in 2023 sales for Novo Nordisk.
Compounded Wegovy and Zepbound may disappear under new FDA rulesThe FDA is restricting compound versions of popular weight-loss drugs due to increased supply from original manufacturers.
How little Denmark got homegrown giant Novo Nordisk to lower Ozempic pricesPharmaceutical pricing conflicts raise challenges globally, as Denmark struggles to afford Novo Nordisk's drugs despite their local production.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-OldsNovo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)Ozempic's explosive sales growth reflects its successful transition from a diabetes treatment to a leading weight loss drug.
Weight-loss drug firm accused of prioritising profits after halting insulin pen productionNovo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030Ozempic, originally a diabetes treatment, has become a major weight loss drug, generating $14 billion in 2023 sales for Novo Nordisk.
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?Novo Nordisk's Ozempic and Wegovy shortage is resolved, enhancing its market position and pricing power.
Fake Ozempic drugs found in US drug supply, FDA warnsCounterfeit Ozempic identified in US supply, prompting FDA warning to healthcare providers and consumers.
The FDA warns patients about counterfeit Ozempic that may be in circulationFDA warns of counterfeit Ozempic affecting patient safety.Report includes details about counterfeit serial numbers.Novo Nordisk acknowledges multiple counterfeit incidents.
Dr. Oz Will Have a Fascinating Conflict of Interest Running Medicare: OzempicMehmet Oz's potential role in leading Medicare raises concerns due to his past connections with Novo Nordisk, makers of Ozempic.
Counterfeit Ozempic: FDA sounds the alarm, warns consumers about fake weight loss drugsPatients should verify prescriptions for Ozempic due to warnings regarding counterfeit products in the drug supply.
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patientsOzempic is FDA approved to reduce risks associated with chronic kidney disease in diabetes patients.
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?Novo Nordisk's Ozempic and Wegovy shortage is resolved, enhancing its market position and pricing power.
Fake Ozempic drugs found in US drug supply, FDA warnsCounterfeit Ozempic identified in US supply, prompting FDA warning to healthcare providers and consumers.
The FDA warns patients about counterfeit Ozempic that may be in circulationFDA warns of counterfeit Ozempic affecting patient safety.Report includes details about counterfeit serial numbers.Novo Nordisk acknowledges multiple counterfeit incidents.
Dr. Oz Will Have a Fascinating Conflict of Interest Running Medicare: OzempicMehmet Oz's potential role in leading Medicare raises concerns due to his past connections with Novo Nordisk, makers of Ozempic.
Counterfeit Ozempic: FDA sounds the alarm, warns consumers about fake weight loss drugsPatients should verify prescriptions for Ozempic due to warnings regarding counterfeit products in the drug supply.
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patientsOzempic is FDA approved to reduce risks associated with chronic kidney disease in diabetes patients.
SAP becomes Europe's biggest company, ASML holds fourth placeSAP's recent stock surge has positioned it as Europe's most valuable company, surpassing Novo Nordisk in market capitalization.
SAP is now the most valuable European public companySAP has become Europe's most valuable company, surpassing Novo Nordisk due to strong investor confidence and growth in cloud-based services.
SAP becomes Europe's biggest company, ASML holds fourth placeSAP's recent stock surge has positioned it as Europe's most valuable company, surpassing Novo Nordisk in market capitalization.
SAP is now the most valuable European public companySAP has become Europe's most valuable company, surpassing Novo Nordisk due to strong investor confidence and growth in cloud-based services.
Weight Loss Drug Will Be Offered for $499 a Month for Some PatientsNovo Nordisk reduces Wegovy's price to $499 for cash-paying patients, but government-insured patients still face high costs.
New Study Finds Wegovy Reduces COVID Death Risk By 33 PercentNovo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.
The Wegovy shortage is causing thousands to turn to copies. What will the FDA do about it?The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.
Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soarNovo Nordisk remains confident in its business despite potential US tariff threats, reporting strong revenue growth fueled by its weight-loss drugs.
Novo Nordisk's Wegovy sales jump on international rolloutsWegovy's sales surged 79%, exceeding expectations, offering reassurance to investors amid growing competition in the obesity drug market.
Wegovy reduced COVID deaths in obese patients, study showsWegovy significantly reduced deaths and illness from COVID-19 during a large study, showcasing its benefits beyond weight loss.
Weight Loss Drug Will Be Offered for $499 a Month for Some PatientsNovo Nordisk reduces Wegovy's price to $499 for cash-paying patients, but government-insured patients still face high costs.
New Study Finds Wegovy Reduces COVID Death Risk By 33 PercentNovo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.
The Wegovy shortage is causing thousands to turn to copies. What will the FDA do about it?The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.
Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soarNovo Nordisk remains confident in its business despite potential US tariff threats, reporting strong revenue growth fueled by its weight-loss drugs.
Novo Nordisk's Wegovy sales jump on international rolloutsWegovy's sales surged 79%, exceeding expectations, offering reassurance to investors amid growing competition in the obesity drug market.
Wegovy reduced COVID deaths in obese patients, study showsWegovy significantly reduced deaths and illness from COVID-19 during a large study, showcasing its benefits beyond weight loss.
Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trialNovo Nordisk's Amycretin shows promise for rapid weight loss, potentially surpassing current leading drugs like Wegovy and Ozempic.
Novo Nordisk Annual Sales Jump on Demand for Ozempic and WegovyNovo Nordisk reported strong earnings in 2024 but expects slower sales growth in 2025 due to competition.The company’s share price has fallen dramatically amid uncertainties in the obesity drug market.
Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trialNovo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.
Novo Nordisk's market value of $570 billion is more than Denmark's annual GDPDanish PM defends economy's resilience amid concerns of over-reliance on Novo Nordisk.
Danish krone weakened by Novo Nordisk share price crashNovo Nordisk's disappointing drug trial results caused a significant drop in its share price, impacting Denmark's economy and currency.
Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trialNovo Nordisk's Amycretin shows promise for rapid weight loss, potentially surpassing current leading drugs like Wegovy and Ozempic.
Novo Nordisk Annual Sales Jump on Demand for Ozempic and WegovyNovo Nordisk reported strong earnings in 2024 but expects slower sales growth in 2025 due to competition.The company’s share price has fallen dramatically amid uncertainties in the obesity drug market.
Novo Nordisk's new weight-loss pill Amycretin beats Wegovy in early trialNovo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.
Novo Nordisk's market value of $570 billion is more than Denmark's annual GDPDanish PM defends economy's resilience amid concerns of over-reliance on Novo Nordisk.
Danish krone weakened by Novo Nordisk share price crashNovo Nordisk's disappointing drug trial results caused a significant drop in its share price, impacting Denmark's economy and currency.
Denmark gets Novo Nordisk to lower Ozempic pricesSanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.
Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimonyNovo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.
Skinny jabs': weight-loss drugs set for new boom as generic versions emergeThe introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.
Europe's most valuable company Novo Nordisk reports a slight increase in profitsNovo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Eli Lilly's GLP-1 sales are declining despite the growing market potential for weight-loss therapies.
Novo Nordisk Foundtion CEO dismisses 'Nokia risk' to Denmark's economyDenmark is currently less vulnerable to economic downturn due to Novo Nordisk's success compared to Finland's previous issues with Nokia.
Denmark gets Novo Nordisk to lower Ozempic pricesSanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.
Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimonyNovo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.
Skinny jabs': weight-loss drugs set for new boom as generic versions emergeThe introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.
Europe's most valuable company Novo Nordisk reports a slight increase in profitsNovo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Eli Lilly's GLP-1 sales are declining despite the growing market potential for weight-loss therapies.
Novo Nordisk Foundtion CEO dismisses 'Nokia risk' to Denmark's economyDenmark is currently less vulnerable to economic downturn due to Novo Nordisk's success compared to Finland's previous issues with Nokia.
I'm the Danish scientist who pioneered injectable drugs like Ozempic. Here are my 3 tips for inventing blockbuster products.Lotte Bjerre Knudsen's research was pivotal in transforming short-acting GLP-1 hormones into successful long-acting diabetes treatments like Ozempic.
Danish town where Ozempic is made has highest rates of overweight children in DenmarkNovo Nordisk's investment success is overshadowed by local socio-economic challenges in Kalundborg, including obesity and inadequate public services.
Chamber, MSF Weigh in on Senate HELP Committee Hearing with Novo Nordisk CEOThe U.S. Chamber opposes price controls, claiming they hinder innovation and access to medications amid scrutiny of rising drug prices.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side EffectsNovo Nordisk's new weight loss drug monlunabant shows promising results but raises concerns due to increased risk of psychiatric side effects compared to placebo.
The next big market for weight-loss drugs: childrenNovo Nordisk's Saxenda can significantly reduce children's BMI, showing potential for FDA approval in a market with currently no approved obesity medications for children.
Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptionsMany patients are struggling to find their medications due to ongoing shortages, despite recent claims from drug manufacturers that supplies have improved.
Sen. Bernie Sanders launches Senate investigation into 'high' pricing of Ozempic, WegovySen. Bernie Sanders investigating high drug prices for Ozempic and Wegovy.
Senate Committee Investigates Ozempic and Wegovy CostsThe Senate Committee is investigating Novo Nordisk's high prices for Ozempic and Wegovy medications, urging the company to consider lowering costs for better accessibility.
Ozempic and Wegovy could soon be challenged by China's generic competitorsIntensifying competition in Chinese market for Novo Nordisk's diabetes drug Ozempic and weight loss treatment Wegovy.